Stergios Moschos
UNC Lineberger Comprehensive Cancer Center · University of North Carolina, Chapel Hill · Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Stergios Moschos as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:37 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07740941 · NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) MelanomaUNC Lineberger Comprehensive Cancer Center · recruiting · Melanoma (Skin Cancer), Melanoma Stage Stage IIIB, Melanoma Stage M1 · principal investigator
- Ph2NCT03765229 · An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV MelanomaUNC Lineberger Comprehensive Cancer Center · completed · Melanoma · principal investigator
- Ph2NCT03620019 · Denosumab + PD-1 in Subjects With Stage III/ IV MelanomaUNC Lineberger Comprehensive Cancer Center · completed · Melanoma Stage Iii, Melanoma Stage Iv, Melanoma · principal investigator
- Ph1NCT03454035 · Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid TumorsUNC Lineberger Comprehensive Cancer Center · recruiting · Tumor, Solid, Pancreatic Cancer, Melanoma · principal investigator
- Ph2NCT03089606 · Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging BiomarkerUNC Lineberger Comprehensive Cancer Center · completed · Melanoma · principal investigator
- N/ANCT01312506 · Collection of Cerebrospinal Fluid and Tumor Tissue in Subjects With Metastatic Melanoma and ControlsUniversity of Pittsburgh · withdrawn · Metastatic Melanoma, CNS Metastases · principal investigator
- Ph1NCT00111696 · Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant MelanomaMedImmune LLC · completed · Malignant Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Development of IDO PET agents for immunotherapyR01CA233904 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2019 to 2023 · $396,007 awarded in 2023Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:37 UTC. The ranking covers the 200 most relevant of 23 PubMed records, and a shared surname and initials can bring in a namesake. All 23 on PubMed
- Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.N Engl J Med · 20121,765 citationsRCR 46.2
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.Lancet Oncol · 20151,309 citationsRCR 40.1
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.N Engl J Med · 20181,088 citationsRCR 35.8
- Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.Lancet Oncol · 2017611 citationsRCR 19.2
- Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.J Clin Oncol · 2013309 citationsRCR 7.5
- 296 citationsRCR 14.5
- 211 citationsRCR 3.8
- PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.Cancer Res · 2014187 citationsRCR 4.4
- Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.J Clin Oncol · 2012126 citationsRCR 2.7
- Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.JCI Insight · 2018126 citationsRCR 3.9